Abstract Sphingosine 1‐phosphate (S1P) is an essential lipid metabolite that signals
through a family of five G protein‐coupled receptors, S1PR1‐S1PR5, to regulate cell …

Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple
sclerosis, activates different sphingosine-1-phosphate receptor (S1PR) subtypes. Its primary …

Background Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor
modulator approved for the treatment of multiple sclerosis. The phosphorylated active …

Abstract Sphingosine‐1‐phosphate (S1P) receptors are widely expressed in the central
nervous system where they are thought to regulate glia cell function. The phosphorylated …

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS
that causes disability in young adults as a result of the irreversible accumulation of …

Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons
with limited treatment options. Emerging evidence shows that FTY720 protects against …

Sphingosine-1-phosphate (S1P) is a pluripotent lipophilic mediator working as a ligand for G-
protein coupled S1P receptors (S1PR), which is currently highlighted as a therapeutic target …

Abstract Background FTY720 (fingolimod, Gilenya™), a structural analog of sphingosine-1-
phosphate (S1P), is the first oral drug approved for treatment the relapsing-remitting form of …

Abstract FTY720 (fingolimod), the sphingosine-1-phosphate (S1P) analogue, has been
experimentally indicated to exert substantial ameliorating effects in animal models of …

Sphingosine-1-phosphate (S1P) is a potent bioactive lipid mediator that acts as a natural
ligand upon binding to five different receptors that are located in astrocytes …